A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Clinical trial NCT00502112 · COMPLETED

Trial details

NCT number: NCT00502112
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Myelodysplastic Syndrome (MDS)

Start date: 2008-03-01
Primary completion: 2010-05-01
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.